Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region

© 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed cli...

Full description

Saved in:
Bibliographic Details
Main Authors: Marwan Sabbagh, Seolheui Han, Sangyun Kim, Hae Ri Na, Jae Hong Lee, Nagaendran Kandiah, Kammant Phanthumchinda, Chuthamanee Suthisisang, Vorapun Senanarong, Ming Chyi Pai, Diatri Narilastri, Ajit M. Sowani, Encarnita Ampil, Amitabh Dash
Other Authors: Barrow Neurological Institute
Format: Review
Published: 2018
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/41174
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.41174
record_format dspace
spelling th-mahidol.411742019-03-14T15:02:06Z Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region Marwan Sabbagh Seolheui Han Sangyun Kim Hae Ri Na Jae Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash Barrow Neurological Institute Konkuk University Seoul National University Bundang Hospital Seoul National University College of Medicine Bobath Memorial Hospital University of Ulsan, College of Medicine Duke-NUS Medical School Singapore Chulalongkorn University Mahidol University National Cheng Kung University University of Indonesia, RSUPN Dr. Cipto Mangunkusumo SAL Hospital and Medical Institute University of Santo Tomas Hospital Eisai Pharmaceuticals India Pvt. Ltd. Medicine © 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions about using donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease (AD). Summary: In a global phase III study (study 326) in patients with moderate-to-severe AD, donepezil 23 mg/day demonstrated significantly greater cognitive benefits versus donepezil 10 mg/day, with a between-treatment difference in mean change in the Severe Impairment Battery score of 2.2 points (p < 0.001) in the overall population and 3.1 points (p < 0.001) in patients with advanced AD. A subanalysis of study 326 demonstrated that the benefits and risks associated with donepezil 23 mg/day versus donepezil 10 mg/day in Asian patients with moderate-to-severe AD were comparable to those in the global study population. Key Message: Donepezil 23 mg is a valuable treatment for patients with AD, particularly those with advanced disease. The APEX emphasized the importance of patient selection (AD severity, tolerability of lower doses of donepezil, and absence of contraindications), a stepwise titration strategy for dose escalation, and appropriate monitoring and counseling of patients and caregivers in the management of patients with AD. 2018-12-11T03:25:44Z 2019-03-14T08:02:06Z 2018-12-11T03:25:44Z 2019-03-14T08:02:06Z 2016-09-09 Review Dementia and Geriatric Cognitive Disorders Extra. Vol.6, No.3 (2016), 382-395 10.1159/000448214 16645464 2-s2.0-84988350405 https://repository.li.mahidol.ac.th/handle/123456789/41174 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84988350405&origin=inward
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Medicine
spellingShingle Medicine
Marwan Sabbagh
Seolheui Han
Sangyun Kim
Hae Ri Na
Jae Hong Lee
Nagaendran Kandiah
Kammant Phanthumchinda
Chuthamanee Suthisisang
Vorapun Senanarong
Ming Chyi Pai
Diatri Narilastri
Ajit M. Sowani
Encarnita Ampil
Amitabh Dash
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
description © 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions about using donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease (AD). Summary: In a global phase III study (study 326) in patients with moderate-to-severe AD, donepezil 23 mg/day demonstrated significantly greater cognitive benefits versus donepezil 10 mg/day, with a between-treatment difference in mean change in the Severe Impairment Battery score of 2.2 points (p < 0.001) in the overall population and 3.1 points (p < 0.001) in patients with advanced AD. A subanalysis of study 326 demonstrated that the benefits and risks associated with donepezil 23 mg/day versus donepezil 10 mg/day in Asian patients with moderate-to-severe AD were comparable to those in the global study population. Key Message: Donepezil 23 mg is a valuable treatment for patients with AD, particularly those with advanced disease. The APEX emphasized the importance of patient selection (AD severity, tolerability of lower doses of donepezil, and absence of contraindications), a stepwise titration strategy for dose escalation, and appropriate monitoring and counseling of patients and caregivers in the management of patients with AD.
author2 Barrow Neurological Institute
author_facet Barrow Neurological Institute
Marwan Sabbagh
Seolheui Han
Sangyun Kim
Hae Ri Na
Jae Hong Lee
Nagaendran Kandiah
Kammant Phanthumchinda
Chuthamanee Suthisisang
Vorapun Senanarong
Ming Chyi Pai
Diatri Narilastri
Ajit M. Sowani
Encarnita Ampil
Amitabh Dash
format Review
author Marwan Sabbagh
Seolheui Han
Sangyun Kim
Hae Ri Na
Jae Hong Lee
Nagaendran Kandiah
Kammant Phanthumchinda
Chuthamanee Suthisisang
Vorapun Senanarong
Ming Chyi Pai
Diatri Narilastri
Ajit M. Sowani
Encarnita Ampil
Amitabh Dash
author_sort Marwan Sabbagh
title Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
title_short Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
title_full Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
title_fullStr Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
title_full_unstemmed Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
title_sort clinical recommendations for the use of donepezil 23 mg in moderate-to-severe alzheimer's disease in the asia-pacific region
publishDate 2018
url https://repository.li.mahidol.ac.th/handle/123456789/41174
_version_ 1763488791515889664